Plus: Vertex, ImmunoGen to create conditioning agents for gene editing, and updates from Church spinout Thymmune, GSK, Regeneron and more

$3.3B deal with Mylan-Upjohn offshoot gives Indian biotech leader pipeline of 20 biosimilars and over $1B in revenue

Ventyx valuation clears $1B, plus AstraZeneca, bluebird, Pfizer, Merck and more

Plus: Mega-rounds for Deep Genomics, Ring and more

Swiss biotech Haya Therapeutics S.A. joins a growing group of RNA-focused newcos raising early venture rounds with a CHF 18 million ($20 million) seed round led by Broadview Ventures to develop

Mylan, Biocon launch long-acting insulin biosimilar in U.S. Mylan N.V. (NASDAQ:MYL) and Biocon Ltd. (NSE:BIOCON; BSE:532523) launched Semglee insulin glargine in the U.S. at a wholesale acquisition

FDA decision is a blow for Sanofi, which markets blockbuster Lantus